rubitecan has been researched along with Soft Tissue Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beach, J; Benjamin, RS; Burgess, MA; Jenkins, J; Papadopoulos, N; Patel, SR; Trent, J | 1 |
1 trial(s) available for rubitecan and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Gastrointestinal Neoplasms; Humans; Leiomyosarcoma; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |